Small ribonucleic acid medicine therapy for Myocardial Infarction: MiRNA-520/373 improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 7/August/2016, 1.41 pm

Amino acid therapy for Diabetes mellitus: Taruine increases islet insulin levels, islet cell mass and glucose tolerance via down regulation of NMDA receptor GluN2A, 28/July/2016, 8.23 am
July 28, 2016
Small RNA-based therapy for pulmonary arterial hypertension: MiRNA-491-5p inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 7/August/2016, 2.58 pm
August 7, 2016
Show all

A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March  2013 issue of Nature  by Prof Dimmler, Boon, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small ribonucleic acid medicine therapy  for Myocardial Infarction: MiRNA-520/373 improves myocardial function after myocardial infarction via  up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10). 

Significance:

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; and (3) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars, there is an urgent need to find: (i)  a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free drug.

By increasing the expression of MiRNA-520/373 in cardiomyocytes, one may prevent ageing-associated (or, stress-associated) decline in cardiac function. Together, this study suggests that pharmacological formulations encompassing “MiRNA-520/373 activators” may be used to improve cardiac function after myocardial infarction

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Small ribonucleic acid medicine therapy  for Myocardial Infarction: MiRNA-520/373 improves myocardial function after myocardial infarction via  up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 7/August/2016,  1.41 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Undisclosed information: How MiRNA-520/373 increases the expression of PNUTS/PPP1R10

Comments are closed.